Genoscience Pharma Is Innovating to Disrupt Cancer Treatment

We are conceptualizing and developing disruptive and innovative science from bench to bedside for improving the conditions of patients in serious unmet medical needs.

Our Approach

As all human living cells, cancer cells need energy to self-renew and survive. Lysosome is a key compartment implicated in cancer cells survival. Among the acquired modifications in cancer cells, changes in lysosomal phenotype and functions are well described, making lysosome a target of interest for novel therapies. Genoscience Pharma focuses on new approaches based on the depriving of cancer cells from essential nutrients by disrupting lysosomal functions.

Discover

Our Pipeline

We leverage our deep knowledge of underlying biological processes to develop innovative and disruptive technology, with potent small molecule drug candidates that directly target lysosomal functions, implicated in the growth, spread and resistance of cancers. We retain global development and commercialization rights of GNS561.

Discover

News

News
June 3, 2019

S.A.B Meeting in Chicago, during ASCO 2019

Scientific Advisory Board Meeting during ASCO 2019   Chicago, USA, June 3, 2019 — Genoscience…
Read More
News
April 17, 2019

Chaim Hurvitz, New Board of Directors Member

Chaim Hurvitz, New Board of Directors Member   Chaim Hurvitz has joined  Genoscience Pharma Board…
Read More
News
December 10, 2018

Most Innovative European Biotech SME for 2018

Most Innovative European Biotech SME for 2018   Bruxelles, Belgium, December 3, 2018 - Company…
Read More

Events

Events
November 8-12, 2019

The AASLD-Liver Meeting 2019

The AASLD - Liver Meeting 2019 - Boston, Massachusetts, USA   We have the pleasure…
Read More
Events
October 16-18, 2019

GMP Symposium 2019

2019 GMP Symposium - Lyon, France DMPK-centred approach to predict Drug Efficacy and Safety  …
Read More
Events
October 2-5, 2019

85èmes Journées Scientifiques de l’AFEF 2019

85èmes Journées Scientifiques de l'AFEF 2019 - Marseille, France   Genoscience Pharma will be present…
Read More

“Translating novel scientific insights into medicines for cancer patients”

Philippe Halfon, CEO of Genoscience Pharma